To improve intracranial disease control following IORT, future strategies should consider closer MRI surveillance and the integration of systemic agents, particularly those with CNS activity, such as immune checkpoint inhibitors in NSCLC or HER2-targeted therapies in breast cancer. Here, ERBB2 is linked to breast carcinoma.